Literature DB >> 11014352

Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study.

M M Boomsma1, C A Stegeman, M J van der Leij, W Oost, J Hermans, C G Kallenberg, P C Limburg, J W Tervaert.   

Abstract

OBJECTIVE: Prediction of relapses in Wegener's granulomatosis (WG) by measuring levels of antineutrophil cytoplasmic antibodies (ANCA) directed against proteinase 3 (PR3) or myeloperoxidase (MPO) remains a controversial issue. To assess the value of serial quantification of ANCA by indirect immunofluorescence (IIF) and antigen-specific enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with WG, a prospective observational study was conducted in patients with WG attending an outpatient clinic in the Netherlands.
METHODS: One hundred patients with WG (85 with PR3-ANCA, 15 with MPO-ANCA) were studied prospectively from 1996 to 1998. Serum samples were obtained and analyzed every 2 months for ANCA levels. Disease activity was prospectively assessed without knowledge of the ANCA levels.
RESULTS: Relapses occurred in 37 of 100 patients (37%). Thirty-four (92%) of the 37 patients showed a rise in the level of ANCA preceding their relapse, as detected by ELISA or IIF. The predictive value of an increase in ANCA titers for relapse was 57% (17 of 30) for cytoplasmic/classic ANCA (cANCA; by IIF), 71% (27 of 38) for PR3-ANCA (by ELISA), and 100% (3 of 3) for MPO-ANCA (by ELISA). The predictive value of a rise in ANCA as measured by ELISA or IIF did not substantially improve following concomitant measurement of the IgG3 subclass of PR3-ANCA. Forty-three percent of patients who showed a rise in cANCA (by IIF) and 29% with a rise in PR3-ANCA (by ELISA) did not subsequently experience a relapse.
CONCLUSION: Serial measurement of ANCA levels is valuable for the early prediction of relapses in patients with WG.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014352     DOI: 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  86 in total

1.  Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis.

Authors:  R H Brons; M C de Jong; N K de Boer; C A Stegeman; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

Review 2.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

4.  Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis.

Authors:  M M Boomsma; D J Stearns-Kurosawa; C A Stegeman; E Raschi; P L Meroni; S Kurosawa; J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 5.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

6.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

Authors:  Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2011-10-29       Impact factor: 7.580

7.  Pituitary involvement in Wegener's granulomatosis: unusual biochemical findings and severe malnutrition.

Authors:  Carmen Tenorio Jimenez; Amparo Montalvo Valdivieso; Gema López Gallardo; Barbara Mcgowan
Journal:  BMJ Case Rep       Date:  2011-11-07

Review 8.  Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?

Authors:  Jan Willem Cohen Tervaert; Jan Damoiseaux
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

9.  Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis.

Authors:  Michael Walsh; Peter A Merkel; Alfred Mahr; David Jayne
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

Review 10.  ANCA-associated small vessel vasculitis: clinical and therapeutic advances.

Authors:  Niveditha Mohan; Gail S Kerr
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.